Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade C 28.98 -0.58% -0.17
CLLS closed down 0.58 percent on Friday, September 21, 2018, on 1.59 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CLLS trend table...

Date Alert Name Type % Chg
Sep 21 50 DMA Support Bullish 0.00%
Sep 21 Stochastic Reached Overbought Strength 0.00%
Sep 21 Overbought Stochastic Strength 0.00%
Sep 20 20 DMA Support Bullish -0.58%
Sep 20 Crossed Above 50 DMA Bullish -0.58%
Sep 20 Up 3 Days in a Row Strength -0.58%
Sep 20 Up 4 Days in a Row Strength -0.58%
Sep 19 20 DMA Support Bullish 1.33%
Sep 19 Up 3 Days in a Row Strength 1.33%
Sep 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.40%

Older signals for CLLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.85
52 Week Low 22.62
Average Volume 154,736
200-Day Moving Average 29.7918
50-Day Moving Average 28.7322
20-Day Moving Average 28.2105
10-Day Moving Average 27.824
Average True Range 0.829
ADX 17.02
+DI 25.8845
-DI 19.7277
Chandelier Exit (Long, 3 ATRs ) 27.483
Chandelier Exit (Short, 3 ATRs ) 27.987
Upper Bollinger Band 30.6999
Lower Bollinger Band 25.7211
Percent B (%b) 0.65
BandWidth 17.648748
MACD Line -0.0515
MACD Signal Line -0.272
MACD Histogram 0.2205
Fundamentals Value
Market Cap 1.04 Billion
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -12.60
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.14
Resistance 3 (R3) 30.15 29.77 29.94
Resistance 2 (R2) 29.77 29.48 29.77 29.88
Resistance 1 (R1) 29.38 29.30 29.19 29.37 29.81
Pivot Point 29.00 29.00 28.91 29.00 29.00
Support 1 (S1) 28.61 28.71 28.42 28.60 28.15
Support 2 (S2) 28.23 28.53 28.23 28.08
Support 3 (S3) 27.84 28.23 28.02
Support 4 (S4) 27.83